Dual GALNT3/T6 inhibition is more effective in reducing epithelial ovarian cancer cell proliferation, migration, and invasion, whilst GALNT6 may promote the generation of more aggressive phenotypes via the EGFR pathway 14, 25. Here, GALNT6 is linked to ovarian carcinoma.